2 results for “ovarian carcinoma”

Set a search alert

Research ArticleOpen accessIn the keywordstNOX (ENOX2) Target for Chemosensitization-Low-Dose Responses in the Hormetic Concentration RangeD. James Morre, Sara Dick, Elena Bosneaga et al.An emerging concept of cancer chemotherapy is that of chemosensitization. Most often applied to the treatment of drug-resistance cancers, chemosensitization has utility when such cancers are rendered drug sensitive through treatment with the sensitizing agent. A particularly striking example of chemosensitization is that encountered with the synthetic isoflavene phenoxodiol where patients with taxane- and/or platinum-resistant ovarian carcinoma once again become … …American Journal of Pharmacology and Toxicology, Vol. 3, Issue 1 · 31 Mar 2008 · 7,573 accessesView PDF Cite

Research ArticleOpen accessIn the abstractRisk of Second Non Breast Malignancies (SNBM) in Relation to Brca1 And Brca2 Mutation Status Following Breast-Conserving Surgery and RadiotherapyYoulia M. Kirova, Alain Fourquet, Alexia Savignoni, Brigitte Sigal-ZafraniWomen from hereditary breast cancer families with BRCA1/2 germline mutation are at increased risk for contralateral breast cancer (BC) and for ovarian cancer (OC). It is less clear whether mutation status influences the rate of SNBM other than OC. In addition, little is known on the risk of OC in individuals from hereditary BC families without identified BRCA mutation. Our … …American Journal of Immunology, Vol. 2, Issue 3 · 30 Sep 2006 · 7,230 accessesView PDF Cite